A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Recruiting now · Phase 1
Conditions studied: Multiple Myeloma
In brief
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma * What side effects may happen from taking linvoseltamab together with another cancer treatment * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Key facts
- Study ID
- NCT05137054
- Run by
- Regeneron Pharmaceuticals
- People needed
- 317
- Starts
- 2022-08-17
- Expected to finish
- 2032-03-24
- Last updated by the study team
- 2026-07-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University Hospital of Salamanca — Salamanca, Spain (enrolling)
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States (enrolling)
- Indiana University Health Simon Cancer Center — Indianapolis, Indiana, United States (enrolling)
- Dana Farber/Harvard Cancer Center — Boston, Massachusetts, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Mayo Clinic — Rochester, Minnesota, United States (enrolling)
- Weill Cornell Medicine/New York Presbyterian Hospital — New York, New York, United States (enrolling)
- New York Presbyterian Hospital Columbia University Medical Center — New York, New York, United States (enrolling)
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
- Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States (enrolling)
- The Ohio State University James Cancer Hospital — Columbus, Ohio, United States (enrolling)
- University of Texas Southwestern — Dallas, Texas, United States (enrolling)
- VA Puget Sound Health Care System — Seattle, Washington, United States (enrolling)
- Centre Hospitalier Universitaire (CHU) de Poitiers — Poitiers, New Aquitaine, France (enrolling)
- Scripps Clinic Torrey Pines — La Jolla, California, United States (enrolling)
- Nantes University Hospital — Nantes, Pays de la Loire Region, France (enrolling)
- Centre Hospitalier Universitaire Angers — Angers, France (enrolling)
- CHU Montpellier - Departement D'Hematologie — Montpellier, France (enrolling)
- Saint Antoine Hospital — Paris, France (enrolling)
- Institut Gustave Roussy — Villejuif, France (enrolling)
- Hospital Henri Mondor — Créteil, Île-de-France Region, France (enrolling)
- Saint Louis Hospital — Paris, Île-de-France Region, France (enrolling)
- Hopital Necker — Paris, Île-de-France Region, France (enrolling)
- Evangelismos General Hospital — Athens, Attica, Greece (enrolling)
- General Hospital of Athens Alexandra — Athens, Greece (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.